TMC names 2024 cohort of cancer treatment innovators

ready to grow

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
From Your Site Articles
The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.
TMC's bootcamp companies have been announced. The 12 startups get to interact with Houston's health tech ecosystem and potentially join TMCi for its next accelerator cohort. Photo via TMC

TMC Innovation hosts 12 life science startups for semiannual accelerator bootcamp

new to hou

The Texas Medical Center's Innovation Factory has brought in 12 life science startups to immerse them in the Houston innovation ecosystem, learn more about their businesses, and select its next cohort for its semiannual accelerator.

Twice a year, the TMC Innovation Factory hosts its HealthTech Accelerator Bootcamp. It a time to see if both sides of the table — TMC and the startups — are a fit for further acceleration. The 12 startups hail from three continents, represent a wide spectrum of specialties, and were widdle down from over 100 applicants.

“These startups are tackling significant challenges facing our health care ecosystem not only locally, but also globally. We are delighted to bring together solutions in the areas of maternal health, enabling care at home, nursing support and education, oncology and neurology, to name a few,” says Devin Dunn, head of the HealthTech Accelerator, in a news release.

Newly appointed entrepreneur in residence, Zaffer Syed, will help in supporting and guiding the cohort. Zaffer has experience as a medtech entrepreneur and has brought health care innovations to market.

“Participation in the Accelerator can certainly fast-track growth for early stage startups,” says Syed in the release. “I am eager to work with the caliber of companies entering bootcamp and to watch what they will achieve with the dedicated support of the TMCi team.”

The 12 companies that were invited to TMCi's bootcamp are as follows, according to TMC.

  • Avia Vascular, from Salt Lake City, Utah, creates Ally, a needle-free blood collection device intended to reduce the need for venipuncture when obtaining blood samples in patients with an established peripheral IV catheter.
  • Queenstown, Singapore-based Biorithm aims to reverse the poor maternal outcomes curve with its remote monitoring system to bring data-driven, accessible, and personalized care to every mother and baby.
  • CranioSense, founded in Bedford, Massachusetts, unlocks the hidden parameters of brain health across the neurological care spectrum with its development of a non-invasive way of assessing and monitoring intracranial pressure.
  • Milwaukee-based Debtle focuses on the patient portion of billing and uses its centralized communications and payment hub to save Revenue Cycle time, improve patient retention, and enable clients to easily resolve their overdue balances.
  • EmpNia Inc., from Minneapolis, enables precision imaging and radiation therapy for all cancer patients by providing an accurate, universal, easy-to-use, and cost-effective respiratory motion management solution.
  • Austin-based Highnote is a generative AI-powered mentor in the nurse’s pocket that build skills and confidence through just-in-time bits of information to make nurses feel supported and better equipped, to provide better patient care, and to improve retention rates.
  • LeQuest, from Rotterdam, Netherlands, aids health care professionals’ skills and knowledge advancement through online stimulation training with its comprehensive remote education solution, resulting in reduced cost of education, increased utilization and better patient outcomes.
  • Lucid Lane, founded in Los Altos, California, provides data-driven digital health solutions to empower both chronic and surgery pain patients, to prevent dependence on prescribed addictive medications and reduces persistent opioid use.
  • RizLab Health Inc., a Princeton, New Jersey company, brings blood cell analysis to patients’ fingertips with its Cytotracker portable device that measures white blood cell counts with a drop of blood to minimize infections from venipuncture in cancer patients.
  • Rose Health, based in Centennial, Colorado, connects occupational therapists and home remodeling service companies to households in need of accessible home modifications to enable homes to age with dignity.
  • Los Angeles-based Spark Neuro offers objective and accessible AI technology for the diagnosis and monitoring of brain health conditions.
  • Vitala, from Stockholm, Sweden, is a digital platform, enables health care providers to prescribe, monitor, and manage diagnoses-specific medical exercises for patients with chronic health conditions.

After the bootcamp, TMCi will decide which of the companies will move on to the six-month accelerator that's slated to start later this year. TMCi recently announced a new accelerator with Denmark, previously announced its spring cohorts.

A new program established at TMC in partnership with Denmark will support the growth of three health tech companies. Photo courtesy of TMC

TMC launches co-hosted health tech accelerator with Denmark

biobridge support

Years ago, the Texas Medical Center established a biobridge to exchange technology and support with Denmark. Now, the two organizations are coming together to advance three health tech startups through a unique accelerator.

TMC and Denmark-based BioInnovation Institute announced today that three companies from BII will join a customized accelerator program that will guide them toward a United States go-to-market strategy. The program will be built off of the TMCi Health Tech Accelerator program.

“At TMC, we are elevating our ability to create curated go-to-market experiences for hand-selected companies that have a relationship with our partners at the BioInnovation Institute and that are seeking to prepare for of market expansion in the U.S.,” says Emily Reiser, associate director of TMC Innovation, in a news release. “We are excited about the opportunity to collaborate with BII and these founders.”

The three startups will head to Houston next week and incubate for six months, working with TMCi advisers and mentors on their individual challenges within commercialization and U.S. expansion. The three companies in the program are:

  • Aiomic, which is developing Aiomic360, an AI platform for postoperative complications. "With automated tracking and real-time risk assessment, Aiomic360 will function as a quality management tool for hospitals, a decision support tool for healthcare practitioners, and an individualized patient empowerment tool for surgical candidates," per the release.
  • Also tapping into AI, Orbit Health's solution, Neptune, is using motion data from smartwatches to track Parkinson’s motor state and treatment response passively. "Its continuous and objective insights enable regular treatment personalization that is needed throughout the course of the disease to optimize patient outcomes and improve quality of life," reads the release.
  • HEI Therapeutics is enabling at-home hypothyroidism management. "The innovative solution includes a patented finger stick blood test and digital patient empowerment tools and aims to significantly reduce the share of patients that is poorly regulated with medication," according to the release.

The TMC and the Ministry of Foreign Affairs of Denmark launched the Biobridge in 2019. BII is a nonprofit organization with a few resources — the Bio Studio, Venture Lab, and Venture House — that support life science startups with resources and even funding of up to €3 million per projects and €1.8 million per company.

“As we strengthen our offering to support visionary healthcare innovators to develop products and solutions to address clear unmet needs, our partnership with Texas Medical Center allows BII startups to gain exposure to US market and ready themselves for US market entry. We are thrilled about this collaboration with the Texas Medical Center which is one of the largest life science ecosystems in the world,” says Tony Cheng-fu Chang, principal at BioInnovation Institute. “Through the customized accelerator program, these three healthcare startups will acquire critical insight to create field-ready plans for bringing their products and solutions to the US market.”

These three health tech startups are moving on in TMCi's accelerator program. Photo courtesy of TMC

TMC names 3 startups to Houston health tech accelerator

onboarding tech

Thee Texas Medical Center named three companies to its accelerator program. The health tech startups will join the program and make key connections to grow their technology and business.

Texas Medical Center Innovation announced this year's cohort for the TMC Innovation Accelerator for HealthTech. The companies attended TMCi's boot camp earlier this year before being named to the cohort.

“It is always exciting to introduce a new group of talented entrepreneurs into our community,” says Tom Luby, director of TMC Innovation, in a news release. “Each with their own goals, and at their individual stage, we’ll work closely together to help them learn, grow and navigate this rich clinical landscape. We are honored to be the bridge between these innovators and the world’s largest medical city.”

The selected startups include Oxford, United Kingdom-based CardMedic, which joins the program by way of TMC's UK BioBridge, an international partnership established to bring cutting-edge health tech startups to the United States by way of Houston. The company's technology is a digital "One Stop Communication Shop" — an extensive library of pre-written scripts that help staff and patients communicate across any barrier, including language, deafness, cognitive impairment, or disability.

“The opportunity to connect with Texas Medical Center member institutions, understand their problem domain, and in what ways that may differ from the United Kingdom is invaluable. We are really excited about learning from the expert team of strategic advisors at the TMCi Accelerator about areas we needed to focus on to grow our company in the United States,” says Rachael Grimaldi, co-founder and CEO of CardMedic.

Chicago-based CareAdvisors, which helps hospitals and clinical social workers connect patients to the best resources and benefits to address social care needs, also joins the TMCi accelerator. The company's technology, the Social Care Automation tool, enables hospitals to generate revenue from preventive health programs and helps health plans reduce overutilization by putting the focus on preventive care.

Roboligent, based in Austin, designs and manufactures robotic and automated physical therapy exercises for patients with upper and lowers limb musculoskeletal issues. This robotic-assisted rehab help promotes recovery while increasing rehab centers’ operational efficiency.

“Introducing a new and innovative product, especially in the medical device field, is a thorough and collaborative effort,” says Bongsu Kim, founder and CEO of Roboligent, in a news release. “TMC’s HealthTech Accelerator is the perfect place to make connections with experts and stakeholders to help guide us in reaching our next milestone.”

Texas Medical Center Innovation announced the seven health tech startups that joined the 2022 accelerator bootcamp. Photo courtesy of TMC

7 health tech startups flock to Houston for TMC bootcamp

ready to accelerate

The Texas Medical Center's innovation arm welcomed seven companies to its 2022 health tech accelerator program bootcamp.

TMC Innovation Accelerator for HealthTech is aimed at supporting early-stage life science startups through fundraising, connecting with mentors and potential customers, and more.

“Healthtech startups who connect with our network will emerge more prepared to access their customers and grow into their markets," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our advisors, members, and partners unlock insights for these entrepreneurs about how to more effectively build a strategic plan for improved market access and adoption. Bootcamp ignites these connections, providing immediate value to entrepreneurs and enabling our team to define a long term plan for continued collaboration."

If selected following the bootcamp, founders will spend six months at TMCi with strategic mentorship, clinical validation, and other customized milestone development from the organization.

“Bootcamp is an intensive period of discovery and mutual selection," says Devin Dunn, head of the Accelerator for HealthTech, in the release. "Founders get a chance better understand everything that TMCi brings to bear and our team has the opportunity to select those growing companies that will add significant value to our community.”

The bootcamp focused on several innovation areas — including surgical devices, access to care, robotics, and hospital efficiency. The participating companies include:

  • CardMedic, headquartered in Oxford, United Kingdom, aims to improve communication between staff and patients across any barrier-language, deafness, cognitive impairment or disability-with an A to Z library of pre-written scripts replicating common clinical conversations.
  • Chicago-baseed CareAdvisors is connecting health plans, hospitals, and community-based organizations to streamline high risk case management and quickly close the loop on care.
  • Endolumik, founded in Morgantown, West Virginia, has developed a fluorescence-guided device that uses near-infrared light to enhance visualization for safer, faster, and more consistent bariatric surgery.
  • Orcha, based in Daresbury, United Kingdom, rigorously reviews apps to help systems, clinicians, patients, or consumers find their way to the best health-related apps.
  • Austin-based Roboligent has created a rehabilitation robot, the Optimo Regen, that provides evidence-based therapeutic interventions for upper and lower limbs.
  • Boston-founded ScienceIO's platform transforms unstructured text into structured records in real-time. The company's core product is a HIPAA-compliant API for real-time text processing and analytics.
  • Semantic Health, founded in Toronto, Canada, uses artificial intelligence to complete secondary reviews of all coded and claims data to optimize revenue cycle management.
The application for future cohorts and more information about the program are available online. The 2022 cohort will join the ranks of TMCi's community of 305 life science startups and 221 TMC Innovation Accelerator companies and will receive access to the center's dozens of member organizations.

"Having a product that the market truly needs is critical but not enough," says Bongsu Kim, founder and CEO of Roboligent, in the release. "Especially for the medical device market, I realize that introducing a new product is a thorough and collaborative effort from a variety of stakeholders and experts. Without knowing the mechanism and the right connection, it seems almost impossible to get into the market. The TMC Innovation Accelerator is the perfect place to make it happen."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings